TABLE 3.
Receptor | Allosteric Effect [Na+] | Estimate of Na+ Affinity | PDB ID (Na+ in Structure) | Reference |
---|---|---|---|---|
DRD4 | Agonist NAM, reduce basal activity | KB = 98 mM | 5WIV (Na+) | Wang et al. (2017) |
DRD2 | Agonist NAM, control of other allosteric ligands | KB = 123.1 mM | 6CM4 | Wang et al. (2017), Draper-Joyce et al. (2018) |
DRD3 | Agonist NAM | KB = 76 mM | 3PBL | Wang et al. (2017) |
MOR | Agonist NAM, control of other allosteric ligands | KB = 7.3 mM | 4DKL | Wang et al. (2017), Livingston et al. (2018) |
DOR | Agonist NAM, control of other allosteric ligands | KB = 24.3 mM | 4N6H (Na+) | Wang et al. (2017) |
A2AR | Agonist NAM | KB = 32.4 mM | 4EIY (Na+) | Wang et al. (2017) |
CLTR1 | Receptor thermostability | EC50 = 39 mM | 6RZ4, 6RZ5 (Na+) | Luginina et al. (2019) |
BLT1 | Agonist NAM | EC50 < 200 mMa | 5X33 (Na+ site blocked by ligand) | Hori et al. (2018) |
V1b | Agonist NAM, required for IP3 signaling | EC50 < 50 mMa | n/a | Koshimizu et al. (2016) |
OXTR | Agonist NAM | EC50 < 200 mMa | n/a | Schiffmann and Gimpl (2018) |
H1R | Agonist NAM | EC50 < 100 mMa | 3RZE | Hishinuma et al. (2017) |
NTSR1 | Agonist NAM | EC50 = 43 mM | 4BUO | White et al. (2018) |
ETA | Agonist NAM | EC50 = 245 mM | n/a | Shihoya et al. (2017) |
Approximately estimated from Na+ titration curves in the referenced papers.